A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE-BRAVE I)
I4V-MC-JAHZ - ClinicalTrials.gov - NCT03616912
The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).
Trial Summary
Age Range
≥18 yearsConditions the trial is for
What the trial is testing?
Could I receive a Placebo?
YesEnrollment Goal
830Trial Dates
Aug 2, 2018 - Mar 9, 2022How long will I be in the trial?
The study will last up to 62 weeks and may include up to 17 visits.Trial Phase
IIILilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo